CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00722631
NCT00722631N/ACompleted
CompareCT.gov

Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT

Kurume University·interventional·Posted Jul 25, 2008·Updated Sep 27, 2012

In Brief

A clinical study evaluating Pioglitazone and Glimepiride for Impaired Glucose Tolerance and 2 related conditions. Completed, enrolled 70 participants across 1 site.

Detailed Summary

There is increasing evidence that inflammation plays a role in progression and destabilization of atherosclerotic plaque. FDG-PET can visualize activated metabolic activity of inflammatory cells. It is possible that FDG-PET can detect atherosclerotic plaque inflammation and that FDG-PET can monitor the effect of pioglitazone on plaque inflammation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance, Type 2 Diabetes Mellitus, Atherosclerosis
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2008
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2009
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.9 years ago

Interventions

Pioglitazonedrug

Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.

Glimepiridedrug

Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.